Helge Hasselmann1, Judith Bellmann-Strobl2, Roland Ricken3, Timm Oberwahrenbrock4, Matthias Rose5, Christian Otte6, Mazda Adli7, Friedemann Paul8, Alexander U Brandt4, Carsten Finke9, Stefan M Gold10. 1. Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany/NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. 2. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany/Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany. 3. Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany. 4. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. 5. Division of Psychosomatic Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany. 6. Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. 7. Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany/Fliedner Klinik Berlin, Berlin, Germany. 8. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany/Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany/Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. 9. Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany/Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany. 10. Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany/Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany stefan.gold@charite.de.
Abstract
BACKGROUND: Depression is a common co-morbidity in patients with multiple sclerosis (MS). While somatic symptoms of MS correlate with depression levels, it is unclear whether the clinical presentation of MS-associated depression differs from patients with "idiopathic" major depressive disorder (MDD). OBJECTIVE: To compare the clinical phenotype of depression among MS and idiopathic MDD patients. METHODS: Mean relative contribution of individual Beck Depression Inventory-II (BDI-II) items was evaluated among n = 139 patients with relapsing-remitting MS and n = 85 MDD patients without somatic illness. Next, comparisons were repeated in n = 38 MS with clinically relevant depressive symptoms (BDI-II > 19) and n = 38 MDD patients matched for sex, age, and depression severity. Finally, the underlying construct of depression was compared across groups using confirmatory factor analysis (CFA). RESULTS: Comparisons on a whole-group level produced the expected differences along somatic/non-somatic symptoms. However, when appropriately controlling for depression severity, age, and sex, only four items contributed differentially to BDI-II total scores in MS versus MDD. CFA suggested that the underlying depression construct is essentially identical in both groups. CONCLUSION: The clinical phenotype of "idiopathic" MDD and MS-associated depression appears similar when adequately examined. The relevance of these findings for psychotherapeutic approaches for MS-associated depression should be explored in future studies.
BACKGROUND:Depression is a common co-morbidity in patients with multiple sclerosis (MS). While somatic symptoms of MS correlate with depression levels, it is unclear whether the clinical presentation of MS-associated depression differs from patients with "idiopathic" major depressive disorder (MDD). OBJECTIVE: To compare the clinical phenotype of depression among MS and idiopathic MDDpatients. METHODS: Mean relative contribution of individual Beck Depression Inventory-II (BDI-II) items was evaluated among n = 139 patients with relapsing-remitting MS and n = 85 MDDpatients without somatic illness. Next, comparisons were repeated in n = 38 MS with clinically relevant depressive symptoms (BDI-II > 19) and n = 38 MDDpatients matched for sex, age, and depression severity. Finally, the underlying construct of depression was compared across groups using confirmatory factor analysis (CFA). RESULTS: Comparisons on a whole-group level produced the expected differences along somatic/non-somatic symptoms. However, when appropriately controlling for depression severity, age, and sex, only four items contributed differentially to BDI-II total scores in MS versus MDD. CFA suggested that the underlying depression construct is essentially identical in both groups. CONCLUSION: The clinical phenotype of "idiopathic" MDD and MS-associated depression appears similar when adequately examined. The relevance of these findings for psychotherapeutic approaches for MS-associated depression should be explored in future studies.
Authors: Mark D Peterson; Paul Lin; Neil Kamdar; Christina N Marsack-Topolewski; Elham Mahmoudi Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-12-23
Authors: Quinten van Geest; Rosa E Boeschoten; Matthijs J Keijzer; Martijn D Steenwijk; Petra Jw Pouwels; Jos Wr Twisk; Johannes H Smit; Bernard Mj Uitdehaag; Jeroen Jg Geurts; Patricia van Oppen; Hanneke E Hulst Journal: Mult Scler Date: 2018-03-28 Impact factor: 6.312